{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:30:53Z","timestamp":1788888653890,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"DOI":"10.7759\/cureus.97370","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:06:11Z","timestamp":1763687171000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Related Central Nervous System Vasculitis Presenting With Recurrent Ischemic Strokes"],"prefix":"10.7759","author":[{"given":"Fumiaki","family":"Henmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Uesaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017, 5:95. 10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain L","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016, 44:51-60. 10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds KL","year":"2019","unstructured":"Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019, 24:435-43. 10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger AF","year":"2016","unstructured":"Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016, 29:806-12. 10.1097\/WCO.0000000000000391","journal-title":"Curr Opin Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000768","article-title":"Pembrolizumab-induced CNS vasculitis: neurologic adverse events due to checkpoint inhibitors","volume":"11","author":"Feng J","year":"2021","unstructured":"Feng J, Ross L, Ontaneda D. Pembrolizumab-induced CNS vasculitis: neurologic adverse events due to checkpoint inhibitors. Neurol Clin Pract. 2021, 11:e30-2. 10.1212\/CPJ.0000000000000768","journal-title":"Neurol Clin Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.20.7.864","article-title":"Measurements of acute cerebral infarction: a clinical examination scale","volume":"20","author":"Brott T","year":"1989","unstructured":"Brott T, Adams HP Jr, Olinger CP, et al.. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989, 20:864-70. 10.1161\/01.str.20.7.864","journal-title":"Stroke"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108265","article-title":"Immune checkpoint inhibitor-related CNS vasculitis - a systematic review and report of 6 cases","volume":"34","author":"Erritz\u00f8e-Jervild M","year":"2025","unstructured":"Erritz\u00f8e-Jervild M, M\u00f8ller SN, Kruuse C, Sten\u00f8r C. Immune checkpoint inhibitor-related CNS vasculitis - a systematic review and report of 6 cases. J Stroke Cerebrovasc Dis. 2025, 34:108265. 10.1016\/j.jstrokecerebrovasdis.2025.108265","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47406","article-title":"Cerebral infarction as a rare adverse event of immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma: a case series","volume":"15","author":"Inoue T","year":"2023","unstructured":"Inoue T, Kumai T, Ohara K, Takahara M. Cerebral infarction as a rare adverse event of immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma: a case series. Cureus. 2023, 15:e47406. 10.7759\/cureus.47406","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2463\/mrms.rev.2021-0140","article-title":"Vessel wall imaging of intracranial arteries: fundamentals and clinical applications","volume":"22","author":"Gomyo M","year":"2023","unstructured":"Gomyo M, Tsuchiya K, Yokoyama K. Vessel wall imaging of intracranial arteries: fundamentals and clinical applications. Magn Reson Med Sci. 2023, 22:447-58. 10.2463\/mrms.rev.2021-0140","journal-title":"Magn Reson Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v7.i12.438","article-title":"Middle cerebellar peduncles: magnetic resonance imaging and pathophysiologic correlate","volume":"7","author":"Morales H","year":"2015","unstructured":"Morales H, Tomsick T. Middle cerebellar peduncles: magnetic resonance imaging and pathophysiologic correlate. World J Radiol. 2015, 7:438-47. 10.4329\/wjr.v7.i12.438","journal-title":"World J Radiol"},{"key":"ref11","article-title":"MR features of diseases involving bilateral middle cerebellar peduncles","volume":"24","author":"Okamoto K","year":"2003","unstructured":"Okamoto K, Tokiguchi S, Furusawa T, Ishikawa K, Quardery AF, Shinbo S, Sasai K. MR features of diseases involving bilateral middle cerebellar peduncles. AJNR Am J Neuroradiol. 2003, 24:1946-54.","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon AC","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, et al.. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:e002890. 10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"ref13","unstructured":"KEYTRUDA\u00ae (pembrolizumab). (2016). Accessed. May 29, 2025: https:\/\/www.pmda.go.jp\/drugs\/2016\/P20161025002\/170050000_22800AMX00696000_G100_1.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat TZ","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, et al.. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015, 33:3193-8. 10.1200\/JCO.2015.60.8448","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/377860-pembrolizumab-related-central-nervous-system-vasculitis-presenting-with-recurrent-ischemic-strokes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:06:12Z","timestamp":1763687172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/377860-pembrolizumab-related-central-nervous-system-vasculitis-presenting-with-recurrent-ischemic-strokes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.97370","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}